Sanofi Comments on Medivation's Rejection of Proposal

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. SPY
7. CVS
8. UNH
9. TMUS
10. LMT

Go back to Sanofi Comments on Medivation's Rejection of Proposal

Medivation (MDVN) PT Raised to $63 at Credit Suisse on M&A Valuation

May 3, 2016 7:27 AM EDT

Credit Suisse analyst Kenneth MacKay raised his price target on Medivation (NASDAQ: MDVN) to $63.00 (from $49.00) as he moves to a M&A valuation. The firm maintained an Outperform rating.

MacKay continues to see Sanofi's $52.50/share offer as significantly undervaluing the pipeline and continue to... More

Stifel Raises Medivation Inc (MDVN) PT to $66 with Company In Play

May 2, 2016 7:19 AM EDT

Stifel analyst, Thomas Shrader, tries to sort through the buyout hype surrounding Medivation (NASDAQ: MDVN) in a note this morning. Recent news reports make it pretty clear Medivation is in play but like many biotechnology stories the value of the company is based on many assumptions. His takeaway is that a fair price would be $66 and possibly as high as $85... More